Home Featured Page 213

Featured

Latest

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and the Post-Psychedelic Challenges Study

Why Perimenopause Belongs in Psychedelic Research

The Psychedelic Practitioner Issue 6: Preparedness (People)

Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application

Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints in GAD

Filament Health Announces Health Canada Approval for Phase II Trial Administering...

Levitee Labs Announces Medical Advisory Board

Red Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete Second...

Entheon Biomedical Provides Update on DMT Human Trial and Announces Regulatory...

Field Trip Announces Intention to Make Applications on Behalf of Patients...

PharmaTher Announces Publication of Research Data for KETABET™

Psychedelic Drug Policy Reform in 2021

Psychedelics 2021: A Year in Review

The McQuade Center for Strategic Research and Development and Mindset Pharma...

Awakn Life Sciences Announces Voluntary Lock-up Agreement Extension with Management, Board...

EDITOR PICKS

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and...

Why Perimenopause Belongs in Psychedelic Research

The Psychedelic Practitioner Issue 6: Preparedness (People)

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and the Post-Psychedelic Challenges Study

Why Perimenopause Belongs in Psychedelic Research

The Psychedelic Practitioner Issue 6: Preparedness (People)

Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application

Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints in GAD

Filament Health Announces Health Canada Approval for Phase II Trial Administering...

Levitee Labs Announces Medical Advisory Board

Red Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete Second...

Entheon Biomedical Provides Update on DMT Human Trial and Announces Regulatory...

Field Trip Announces Intention to Make Applications on Behalf of Patients...

PharmaTher Announces Publication of Research Data for KETABET™

Psychedelic Drug Policy Reform in 2021

Psychedelics 2021: A Year in Review

The McQuade Center for Strategic Research and Development and Mindset Pharma...

Awakn Life Sciences Announces Voluntary Lock-up Agreement Extension with Management, Board...

EDITOR PICKS

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and...

Why Perimenopause Belongs in Psychedelic Research

The Psychedelic Practitioner Issue 6: Preparedness (People)

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY